Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 31
Filtrer
1.
Eur J Surg Oncol ; 42(12): 1827-1833, 2016 Dec.
Article de Anglais | MEDLINE | ID: mdl-27769634

RÉSUMÉ

BACKGROUND: Two thirds of node-positive breast cancer patients have limited pN1 disease and could benefit from a less extensive axillary lymph node dissection (ALND). METHODS: 172 breast cancers patients requiring an ALND were prospectively enrolled in the Sentibras Protocol of Axillary Reverse Mapping (ARM). Radioisotope was injected in the ipsilateral hand the day before surgery. ALND was standard. Removed lymph nodes were classified into non radioactive nodes and radioactive nodes (ARM nodes). Among ARM nodes, nodes located in the upper outer part of the axilla, above the second intercostal brachial nerve and lateral to the lateral thoracic vein were identified as "zone D ARM nodes". The main objective was: feasibility of identification of the zone D ARM nodes. Secondary objectives were: metastatic involvement and lymphedema rate. RESULTS: 100% of patients had ARM nodes identified. The "zone D ARM nodes" were identified in 92% of cases. The rate of metastatic nodes was 60% in the all cohort, 31% in ARM nodes and 9% in zone D ARM nodes. Among those, metastatic rate was 6% in patients undergoing ALND for a positive sentinel node biopsy, 6% in case of primary ALND versus 14% after neo-adjuvant chemotherapy (p < 0.05). After 34 months of median follow up, 27% of interviewed patients had a lymphedema. CONCLUSION: The ARM technique reliably identifies the "zone D ARM nodes". These nodes can also easily be identified using knowledge of axillary anatomy. In selected patients, a selective ALND sparing the zone D ARM nodes could be performed.


Sujet(s)
Tumeurs du sein/chirurgie , Lymphadénectomie/méthodes , Noeud lymphatique sentinelle/anatomopathologie , Adulte , Sujet âgé , Antinéoplasiques/usage thérapeutique , Aisselle/chirurgie , Lymphoedème après cancer du sein/épidémiologie , Tumeurs du sein/anatomopathologie , Protocoles cliniques , Études de faisabilité , Femelle , Humains , Noeuds lymphatiques/anatomopathologie , Adulte d'âge moyen , Traitement néoadjuvant , Complications postopératoires/épidémiologie , Biopsie de noeud lymphatique sentinelle
2.
Ann Oncol ; 24(2): 370-376, 2013 Feb.
Article de Anglais | MEDLINE | ID: mdl-23051951

RÉSUMÉ

BACKGROUND: To evaluate whether predictive factors of axillary lymph node metastasis in female breast cancer (BC) are similar in male BC. PATIENTS AND METHODS: From January 1994 to May 2011, we recorded 80 non-metastatic male BC treated at Institut Curie (IC). We analysed the calibration and discrimination performance of two nomograms [IC, Memorian Sloan-Kettering Cancer Center (MSKCC)] originally designed to predict axillary lymph node metastases in female BC. RESULTS: About 55% and 24% of the tumours were pT1 and pT4, respectively. Nearly 46% demonstrated axillary lymph node metastasis. About 99% were oestrogen receptor positive and 94% HER2 negative. Lymph node status was the only significant prognostic factor of overall survival (P = 0.012). The area under curve (AUC) of IC and MSKCC nomograms were 0.66 (95% CI 0.54-0.79) and 0.64 (95% CI 0.52-0.76), respectively. The calibration of these two models was inadequate. CONCLUSIONS: Multi-variate models designed to predict axillary lymph node metastases for female BC were not effective in our male BC series. Our results may be explained by (i) small sample size (ii) different biological determinants influencing axillary metastasis in male BC compared with female BC.


Sujet(s)
Tumeur du sein de l'homme/anatomopathologie , Métastase lymphatique , Récepteur ErbB-2/métabolisme , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Aisselle , Tumeur du sein de l'homme/mortalité , Tumeur du sein de l'homme/chirurgie , Femelle , Humains , Lymphadénectomie , Noeuds lymphatiques/anatomopathologie , Noeuds lymphatiques/chirurgie , Mâle , Adulte d'âge moyen , Nomogrammes , Pronostic , Études rétrospectives , Biopsie de noeud lymphatique sentinelle
3.
Ann Oncol ; 23(5): 1170-1177, 2012 May.
Article de Anglais | MEDLINE | ID: mdl-21896543

RÉSUMÉ

BACKGROUND: Our objective was to assess the global cost of the sentinel lymph node detection [axillary sentinel lymph node detection (ASLND)] compared with standard axillary lymphadenectomy [axillary lymph node dissection (ALND)] for early breast cancer patients. PATIENTS AND METHODS: We conducted a prospective, multi-institutional, observational, cost comparative analysis. Cost calculations were realized with the micro-costing method from the diagnosis until 1 month after the last surgery. RESULTS: Eight hundred and thirty nine patients were included in the ASLND group and 146 in the ALND group. The cost generated for a patient with an ASLND, with one preoperative scintigraphy, a combined method for sentinel node detection, an intraoperative pathological analysis without lymphadenectomy, was lower than the cost generated for a patient with lymphadenectomy [€ 2947 (σ = 580) versus € 3331 (σ = 902); P = 0.0001]. CONCLUSION: ASLND, involving expensive techniques, was finally less expensive than ALND. The length of hospital stay was the cost driver of these procedures. The current observational study points the heterogeneous practices for this validated and largely diffused technique. Several technical choices have an impact on the cost of ASLND, as intraoperative analysis allowing to reduce rehospitalization rate for secondary lymphadenectomy or preoperative scintigraphy, suggesting possible savings on hospital resources.


Sujet(s)
Tumeurs du sein/économie , Tumeurs du sein/anatomopathologie , Carcinomes/économie , Carcinomes/anatomopathologie , Lymphadénectomie/économie , Biopsie de noeud lymphatique sentinelle/économie , Sujet âgé , Algorithmes , Aisselle/anatomopathologie , Tumeurs du sein/diagnostic , Tumeurs du sein/chirurgie , Carcinomes/diagnostic , Carcinomes/chirurgie , Coûts et analyse des coûts , Évolution de la maladie , Femelle , France , Chirurgie générale/organisation et administration , Humains , Durée du séjour/économie , Durée du séjour/statistiques et données numériques , Lymphadénectomie/méthodes , Noeuds lymphatiques/anatomopathologie , Noeuds lymphatiques/chirurgie , Métastase lymphatique/diagnostic , Oncologie médicale/organisation et administration , Adulte d'âge moyen , Stadification tumorale/économie , Études prospectives , Sociétés médicales
4.
J Fr Ophtalmol ; 32(6): 420-4, 2009 Jun.
Article de Français | MEDLINE | ID: mdl-19523714

RÉSUMÉ

PURPOSE: Obstructive sleep apnea syndrome (OSAS) is a very common disease and has recently been increasingly incriminated in the initiation and progression of numerous cardiovascular, neurologic, and ophthalmologic diseases. In ophthalmologic practice, it may be related to glaucoma, nonarteritic anterior ischemic optic neuropathy, visual field defects, papilledema, central serous chorioretinopathy, and floppy eyelid syndrome. Because of personal observations, we investigated its link with retinal vein occlusion (RVO). OBSERVATION: We report the observations on three patients who presented with retinal vein occlusion and who were investigated positively for OSAS, including patients with no conventional vascular risk factors. DISCUSSION: The local and systemic effects of OSAS could explain, in some patients, the occurrence and/or the aggravation of RVO. The first-stage effects of OSAS are nocturnal hypoxemia, hypercapnia, intrathoracic pressure changes, arousals, and sleep fragmentation. RVO could be a consequence of a slow-down of blood flow circulation secondary to hypoxemia and elevated nocturnal intracranial pressure. The arousals cause an additional acute increase in arterial blood pressure. Ancillary effects include increased platelet aggregability, increased sympathic activation, oxidative stress, vascular endothelial dysfunction, inflammation, and metabolic dysregulation. CONCLUSION: This short series for the first time reports RVO patients presenting with OSAS. This suggests that OSAS, by acting on retinal microcirculation, could be an additional risk factor for the occurrence or the aggravation of RVO. Further studies are needed to confirm this possible relationship.


Sujet(s)
Occlusion veineuse rétinienne/étiologie , Syndrome d'apnées obstructives du sommeil/complications , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen
5.
Ann Oncol ; 17(8): 1228-33, 2006 Aug.
Article de Anglais | MEDLINE | ID: mdl-16740599

RÉSUMÉ

BACKGROUND: We compared the impact of neoadjuvant chemotherapy on pathologic response and outcome in operable invasive lobular breast carcinoma (ILC) and invasive ductal breast carcinoma (IDC). PATIENTS AND METHODS: We extracted from our database all patients with pure invasive lobular (n=118, 14%) or pure invasive ductal carcinomas (n=742, 86%). Their treatment included neoadjuvant chemotherapy, adapted surgery, radiotherapy and adjuvant hormonal treatment. RESULTS: Compared with IDC, ILC presented with larger tumors (T3: 38.1% versus 21.4%, P=0.0007), more N0 nodes status (55.9% versus 43.3%, P=0.01), less inflammatory tumors (5.9% versus 11.8%, P=0.01), more hormone receptor positivity (65.5% versus 38.8%), lower histological grade (P<0.0001). Final surgery was a mastectomy in 70% of patients with ILC (34% were reoperated after initial partial mastectomy) and in 52% of IDC after 8% of reoperation (P=0.006). A pathological complete response (pCR) was achieved in 1% of ILC and 9% of IDC (P=0.002). The outcome at 60 months was significantly better for ILC, but histologic type was not an independent factor for survival in multivariate analysis. CONCLUSIONS: ILC appeared less responsive to chemotherapy but presented a better outcome than IDC. While new information on biological features of ILC is needed, we consider that neoadjuvant endocrine therapy in hormone receptor-positive ILC may be a more adapted approach than neoadjuvant chemotherapy.


Sujet(s)
Tumeurs du sein/traitement médicamenteux , Carcinome canalaire/traitement médicamenteux , Carcinome lobulaire/traitement médicamenteux , Traitement néoadjuvant , Tumeurs du sein/mortalité , Tumeurs du sein/anatomopathologie , Carcinome canalaire/mortalité , Carcinome canalaire/anatomopathologie , Carcinome lobulaire/mortalité , Carcinome lobulaire/anatomopathologie , Femelle , Humains , Études rétrospectives , Analyse de survie
6.
Gynecol Oncol ; 102(3): 523-9, 2006 Sep.
Article de Anglais | MEDLINE | ID: mdl-16504274

RÉSUMÉ

OBJECTIVES: To evaluate the morbidity and therapeutic value of surgery after concurrent chemoradiotherapy and brachytherapy in a multicentric series of patients with advanced cervical cancer. METHODS: Patients with stage IB2 to IVA cervical cancer treated with concurrent chemoradiotherapy and pelvic radiotherapy followed by brachytherapy and surgery from seven participating French comprehensive cancer centers were enrolled. The surgical treatment consisted of a hysterectomy, which ranged from radical hysterectomy to anterior pelvic exenteration, and lymph node resection. Acute toxicity, pathological response, overall, and disease-free survival were assessed for each pathological response to therapy. RESULTS: One hundred seventy-five patients were enrolled from September 1987 to June 2002. The median age was 44 years [27;75]. Patients distribution according to clinical classification was as follows: 41 stage IB2, 18 IIA, 77 IIB, 12 IIIA, 14 IIIB, and 13 IVA. Forty-six patients experienced 51 postoperative complications. Thirty-three patients experienced grade 2 morbidity (18.9%, 33/175), among whom 19 experienced urinary complications (57.5%, 19/175). No post treatment mortality was observed. Grade 3 toxicity rate was 6.9% (12/175). Pathological complete response rate was 38% (67/175). After a median follow-up of 36 months, overall survival and disease-free survival were significantly better in patients who had a pathological complete response to therapy than those who achieved a partial pathological response (P < 0.0001). CONCLUSION: Surgery after concurrent chemoradiotherapy and brachytherapy for advanced cervical cancer leads to an acceptable morbidity. Furthermore, surgery allows evaluation of the pathological response to therapy and improves local control in the case of partial pathological response.


Sujet(s)
Curiethérapie , Tumeurs du col de l'utérus/chirurgie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Curiethérapie/effets indésirables , Association thérapeutique , Survie sans rechute , Femelle , Humains , Hystérectomie/effets indésirables , Adulte d'âge moyen , Radiothérapie adjuvante , Études rétrospectives , Taux de survie , Tumeurs du col de l'utérus/traitement médicamenteux , Tumeurs du col de l'utérus/radiothérapie
7.
Gynecol Obstet Fertil ; 32(12): 1039-46, 2004 Dec.
Article de Français | MEDLINE | ID: mdl-15589780

RÉSUMÉ

OBJECTIVE: Axillary padding without drainage appeared to be a valuable alternative technique to vacuum drainage. The technique employs local muscles or the axillary aponeurosis for padding. We report here the clinical evaluation of muscular padding without drainage. The analysis of these results prompted us to also do a literature search for other alternatives aimed at reducing morbidity due to vacuum drainage. PATIENTS AND METHODS: Muscular padding was prospectively performed by 8 different surgeons on a total of 152 patients at the Centre Rene-Huguenin (Saint-Cloud, France). Follow-up has attained 3.5 years. A comparative assessment of pain was conducted in 30 patients operated on with vacuum drainage. RESULTS: This technique is easy to learn and reproducible. It facilitates post-operative follow-up, always allowing discharge at the 2nd or 3rd post-operative day without any home nursing. The late sequels are not increased. In contrast, pain was twice more intense during the first post-operative weeks compared with vacuum drainage, and the seroma rate was also increased. DISCUSSION AND CONCLUSION: Despite good efficacy, this worsening of pain is a major obstacle to the routine use of muscular padding. A technical improvement has been published very recently where the axillary aponeurosis was used to pad the axilla. It seems to be equally efficient but less painful than muscular padding. This technique is under clinical evaluation and could appear as a valuable option to vacuum drainage. Other alternatives are discussed. Most studies lack a direct comparison with vacuum drainage and a satisfactory evaluation of quality of life is also omitted. New studies with quality of life scales are ongoing. They should allow us to choose options that take this aspect into account in the future.


Sujet(s)
Tumeurs du sein/anatomopathologie , Tumeurs du sein/chirurgie , Lymphadénectomie/méthodes , Aisselle , Femelle , Études de suivi , Humains , Métastase lymphatique , Douleur postopératoire/épidémiologie , Qualité de vie , Aspiration (technique) , Lambeaux chirurgicaux , Techniques de suture , Résultat thérapeutique
9.
Crit Care Med ; 29(7): 1311-7, 2001 Jul.
Article de Anglais | MEDLINE | ID: mdl-11445676

RÉSUMÉ

OBJECTIVE: It is not always feasible to culture immediately bacteriologic samples of protected pulmonary specimens on a 24-hr basis before starting antibiotic treatment. We have evaluated the effect of delaying the culture of immediate plugged telescoping catheter (PTC) samples performed before starting antibiotherapy. DESIGN: Prospective paired comparisons study. SETTING: Intensive care unit in a university hospital. PATIENTS: Ninety-nine PTCs were performed on 68 intensive care unit patients suspected of nosocomial or community- acquired bacterial pneumonia. INTERVENTION: PTC samples were divided into two aliquots: one for immediate (H0) analysis and one for storage at 4 degrees C (H24) for 24 hrs before being cultured. MEASUREMENTS AND MAIN RESULTS: The results from these delayed cultures (H24) were compared with those from immediate ones (H0). All negative H0 samples (n = 59) were also negative at H24. Forty PTCs yielded one or more microorganisms, with a total of 69 microorganisms in one or both samples. H0 and H24 cultures were concordant in 119 of 128 (97.9%) cases (kappa coefficient value 0.79) with a threshold of 103 colony-forming units (cfu)/mL. Agreement between paired cultures was very good. The bias calculated as the mean difference between paired culture results was 0.128 +/- 1.024 (Deltalog). Concordance using the 103 cfu/mL threshold (102/107 cases, kappa coefficient value 0.82) and agreement were enhanced (0.067 +/- 0.645) when possible contaminants were excluded (n = 21). CONCLUSIONS: Storing PTC specimens for 24 hrs at 4 degrees C is an acceptable alternative when culturing cannot be performed immediately. This allows starting antibiotic treatment without any delay.


Sujet(s)
Techniques de culture cellulaire/méthodes , Pneumopathie bactérienne/diagnostic , Manipulation d'échantillons/méthodes , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Bronchoscopie , Numération de colonies microbiennes , Infections communautaires/diagnostic , Infections communautaires/traitement médicamenteux , Infection croisée/diagnostic , Infection croisée/traitement médicamenteux , Femelle , Humains , Unités de soins intensifs , Méthode des moindres carrés , Mâle , Analyse appariée , Adulte d'âge moyen , Pneumopathie bactérienne/traitement médicamenteux , Études prospectives , Réfrigération , Sensibilité et spécificité , Facteurs temps
10.
AIDS ; 15(1): 23-31, 2001 Jan 05.
Article de Anglais | MEDLINE | ID: mdl-11192865

RÉSUMÉ

OBJECTIVE: To study the safety of discontinuing cytomegalovirus (CMV) maintenance therapy among patients with cured CMV retinitis receiving highly active antiretroviral therapy (HAART). METHODS: Patients with a history of CMV retinitis who were receiving anti-CMV maintenance therapy and who had a CD4 cell count > 75 x 10(6) cells/l and a plasma HIV RNA level < 30000 copies/ml while on HAART were included in a multicentre prospective study. Maintenance therapy for CMV retinitis was discontinued at enrolment and all the patients were monitored for 48 weeks by ophthalmological examinations and by determination of CMV markers, CD4 cell counts and plasma HIV RNA levels. T helper-1 anti-CMV responses were assessed in a subgroup of patients. The primary study endpoint was recurrence of CMV disease. RESULTS: At entry, the 48 assessable patients had been taking HAART for a median of 18 months. The median CD4 cell count was 239 x 10(6) cells/l and the median HIV RNA load was 213 copies/ml. Over the 48 weeks, 2 of the 48 patients had a recurrence of CMV disease. The cumulative probability of CMV retinitis relapse was 2.2% at week 48 (95% confidence interval, 0.4-11.3) and that of all forms of CMV disease 4.2%. CMV blood markers remained negative throughout follow-up. The proportion of patients with CMV-specific CD4 T cell reactivity was 46% at baseline and 64% at week 48. CONCLUSIONS: CMV retinitis maintenance therapy may be safely discontinued in patients with CD4 cell counts above 75 x 10(6) cells/l who have been taking HAART for at least 18 months.


Sujet(s)
Infections opportunistes liées au SIDA/traitement médicamenteux , Agents antiVIH/usage thérapeutique , Rétinite à cytomégalovirus/traitement médicamenteux , Infections opportunistes liées au SIDA/épidémiologie , Infections opportunistes liées au SIDA/immunologie , Infections opportunistes liées au SIDA/virologie , Adulte , Thérapie antirétrovirale hautement active , Numération des lymphocytes CD4 , Cytomegalovirus/immunologie , Rétinite à cytomégalovirus/épidémiologie , Rétinite à cytomégalovirus/immunologie , Rétinite à cytomégalovirus/virologie , Oeil/physiopathologie , Femelle , Études de suivi , Humains , Incidence , Mâle , Adulte d'âge moyen , Études prospectives , ARN viral/sang
11.
Clin Infect Dis ; 31(1): 201-2, 2000 Jul.
Article de Anglais | MEDLINE | ID: mdl-10913427

RÉSUMÉ

We report on the first case of documented Helicobacter cinaedi septic arthritis in an immunocompetent heterosexual young man. The patient presented no identified risk factor except for contact with animals that have been incriminated as a possible source of infection, particularly for these patients. Despite prolonged bacteremia, the response to long-term therapy with ciprofloxacin and rifampin was excellent.


Sujet(s)
Arthrite infectieuse/microbiologie , Bactériémie/microbiologie , Infections à Helicobacter/complications , Immunocompétence , Synovite/microbiologie , Adulte , Anti-infectieux/usage thérapeutique , Arthrite infectieuse/traitement médicamenteux , Arthrite infectieuse/immunologie , Bactériémie/traitement médicamenteux , Bactériémie/immunologie , Ciprofloxacine/usage thérapeutique , Helicobacter/génétique , Helicobacter/croissance et développement , Helicobacter/isolement et purification , Infections à Helicobacter/traitement médicamenteux , Infections à Helicobacter/immunologie , Humains , Mâle , Rifampicine/usage thérapeutique , Synovite/traitement médicamenteux
12.
Am J Respir Crit Care Med ; 161(1): 104-9, 2000 Jan.
Article de Anglais | MEDLINE | ID: mdl-10619805

RÉSUMÉ

The cost of mechanical ventilation (MV) is high. Efforts to reduce this cost, as long as they are not detrimental for the patients, are needed. MV with heat and moisture exchangers (HME) changed every 48 h is safe, efficient, and cost-effective. Preliminary reports suggest that the life span of these filters may be prolonged. We determined prospectively whether a hygroscopic and hydrophobic HME (Hygrobac-Dar; Mallinckrodt) provided safe and efficient heating and humidification of the inspired gases when changed only once a week. Patients who were considered to require mechanical ventilation for more than 48 h were included in the study. HMEs were initially set for 7 d. Efficient airway heating and humidification were assessed by clinical parameters (number of tracheal suctionings and instillations required, peak airway pressures) and hygrometric measurements performed by psychrometry. Resistance was measured from Day 0 to Day 7. Bacterial colonization of circuits and HMEs was studied. A total of 377 days of mechanical ventilation with 60 HMEs was studied. Clinical parameters and hygrometric measurements did not change between Day 0 and Day 7. Mean absolute humidity was 30.3 +/- 1.3 mg H(2)O/L on Day 0 and 30.8 +/- 1.5 mg H(2)O/L on Day 7 (p = 0.7). Endotracheal tube occlusion never occurred. Three HMEs were replaced prematurely because of insufficient absolute humidity. This rare event occurred only in patients with COPD and after the third day of use. In addition, the absolute humidity delivered by the HMEs was significantly lower in patients with COPD than in the rest of the population. Resistance did not change from Day 0 to Day 7 (2.4 +/- 0.3 versus 2.7 +/- 0.3 cm H(2)O/L/s; p = 0.4). Bacterial samples of both circuits and ventilator sides of HMEs were sterile in most cases. We conclude that mechanical ventilation can be safely conducted in non-COPD patients using an HME changed only once a week, leading to substantial cost savings (about $110,000 per year if these findings were applied to the university-affiliated hospitals in Paris).


Sujet(s)
Matériel jetable , Filtration/instrumentation , Température élevée , Humidité , Ventilation artificielle/normes , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Résistance des voies aériennes , Bactéries/croissance et développement , Bactéries/isolement et purification , Infections bactériennes/prévention et contrôle , Numération de colonies microbiennes , Analyse coût-bénéfice , Matériel jetable/microbiologie , Contamination de matériel , Femelle , Humains , Mâle , Adulte d'âge moyen , Études prospectives , Insuffisance pulmonaire/physiopathologie , Insuffisance pulmonaire/thérapie , Ventilation artificielle/économie , Ventilation artificielle/instrumentation , Unité de soins intensifs respiratoires , Sécurité
13.
Pathol Biol (Paris) ; 48(9): 825-31, 2000 Nov.
Article de Français | MEDLINE | ID: mdl-11141918

RÉSUMÉ

Among the proteases involved in the tumor invasion process, components of the plasminogen activator system (plasminogen activator type-urokinase uPA, its membrane receptor uPAR and its two inhibitors PAI-1 and PAI-2) appear to define high risk patients in primary breast cancer. As individual analysis of each component of the plasminogen activator system does not reflect the complex interactions between the different components, we studied the prognostic impact of a dissemination risk index combining the four variables. We found that this index was the most powerful prognostic factor, particularly in node-negative patients.


Sujet(s)
Marqueurs biologiques tumoraux/analyse , Tumeurs du sein/composition chimique , Inhibiteur-1 d'activateur du plasminogène/analyse , Inhibiteur-2 d'activateur du plasminogène/analyse , Récepteurs de surface cellulaire/analyse , Indice de gravité de la maladie , Activateur du plasminogène de type urokinase/analyse , Adulte , Tumeurs du sein/mortalité , Tumeurs du sein/chirurgie , Femelle , Humains , Tables de survie , Lymphadénectomie , Métastase lymphatique , Mastectomie , Adulte d'âge moyen , Métastase tumorale , Protéines tumorales/analyse , Protéines tumorales/sang , Pronostic , Récepteurs des oestrogènes/analyse , Récepteurs à la progestérone/analyse , Récepteurs à l'activateur du plasminogène de type urokinase , Études rétrospectives , Risque , Analyse de survie , Résultat thérapeutique
14.
J Clin Oncol ; 17(10): 3048-57, 1999 Oct.
Article de Anglais | MEDLINE | ID: mdl-10506599

RÉSUMÉ

PURPOSE: To study interactions between disease-free survival (DFS) and four components of the plasminogen activator system: urokinase-type plasminogen activator (uPA), its two inhibitors (PAI-1 and PAI-2), and its membrane receptor uPAR. PATIENTS AND METHODS: We conducted a retrospective study of 499 primary breast cancer patients (median follow-up, 6 years). uPA, PAI-1, and PAI-2 were determined on cytosols and uPAR on solubilized pellets, using enzyme-linked immunoadsorbent assay kits (American Diagnostica, Greenwich, CT). Classical univariate and multivariate statistical methods were used together with multiple correspondence analysis to graphically examine interactions between the variables and outcome. RESULTS: By univariate analysis, higher uPA and PAI-1 values were significantly related to shorter DFS (P =.002; P <.00002). PAI-2 was not significantly related to DFS, although patients with high and very low PAI-2 values had a longer DFS. Multiple correspondence analysis showed the parallel impact of uPA and PAI-1 on outcome, and the clearly different behavior of PAI-2 compared with PAI-1. The prognostic contribution of uPAR seemed weak by both methods. A dissemination risk index [uPA x PAI-1/(PAI-2 + 1)], taking into account the modulation of uPA proteolytic activity by the ratio of its two inhibitors, was then tested. Dissemination risk index was selected as an independent variable in the Cox model in the overall population (P <.000001) and in node-positive patients (P <.00001). It was the only variable selected in node-negative patients (P =. 003). CONCLUSION: A dissemination risk index determined on primary tumor and taking into account the different effects of PAI-1 and PAI-2 on uPA can be of major help in clinical management of breast cancer, particularly in node-negative patients.


Sujet(s)
Marqueurs biologiques tumoraux/analyse , Tumeurs du sein/composition chimique , Inhibiteur-1 d'activateur du plasminogène/analyse , Inhibiteur-2 d'activateur du plasminogène/analyse , Activateur du plasminogène de type urokinase/analyse , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Tumeurs du sein/classification , Femelle , Humains , Adulte d'âge moyen , Pronostic , Récepteurs de surface cellulaire/analyse , Études rétrospectives , Appréciation des risques
15.
Drugs ; 57(5): 743-50, 1999 May.
Article de Anglais | MEDLINE | ID: mdl-10353299

RÉSUMÉ

Bacterial infections of the male genital tract in young men (<35 years old) are primarily caused by sexually transmissible bacteria like Chlamydia trachomatis, Neisseria gonorrhoeae but also Mycoplasma or Haemophilus spp. In men aged over 35 years, Enterobacteriaceae are more frequently involved in urethritis, epididymitis and prostatitis. The traditional treatments suggested like tetracyclines or erythromycin are less effective since bacterial resistance is increasingly frequent, particularly in N. gonorrhoeae. Moreover, patient compliance with these drug treatments are frequently not well observed. New therapies including short term therapy with fluoroquinolones or azalides (e.g. azithromycin) are very effective and easy to use and thus eliminate any problem of compliance. However, we have to be vigilant for the emergence of resistant strains to these agents.


Sujet(s)
Antibactériens/usage thérapeutique , Maladies de l'appareil génital mâle/traitement médicamenteux , Maladies sexuellement transmissibles bactériennes/traitement médicamenteux , Épididymite/traitement médicamenteux , Humains , Mâle , Prostatite/traitement médicamenteux , Urétrite/traitement médicamenteux
16.
Int J Cancer ; 76(3): 325-30, 1998 May 04.
Article de Anglais | MEDLINE | ID: mdl-9579567

RÉSUMÉ

Since tamoxifen is widely used in breast cancer treatment and has been proposed for the prevention of breast cancer, its endometrial iatrogenic effects must be carefully examined. We have investigated the association between endometrial cancer and tamoxifen use or other treatments in women treated for breast cancer in a case-control study. Cases of endometrial cancer diagnosed after breast cancer (n = 135) and 467 controls matched for age, year of diagnosis of breast cancer and hospital and survival time with an intact uterus were included. Women who had received tamoxifen were significantly more likely to have endometrial cancer diagnosed than those who had not (crude relative risk = 4.9, p = 0.0001). Univariate and adjusted analyses showed that the risk increased with the length of treatment (p = 0.0001) or the cumulative dose of tamoxifen received (p = 0.0001), irrespective of the daily dose. Women who had undergone pelvic radiotherapy also had a higher risk (crude relative risk = 7.8, p = 0.0001). After adjusting for confounding factors, the risk was higher for tamoxifen users (p = 0.0012), treatment for more than 3 years (all p < 0.03) and pelvic radiotherapy (p = 0.012). Women who had endometrial cancer and had received tamoxifen had more advanced disease and poorer prognosis than those with endometrial cancer who had not received this treatment. Our results suggest a causal role of tamoxifen in endometrial cancer, particularly when used as currently proposed for breast cancer prevention. Pelvic radiotherapy may be an additional iatrogenic factor for women with breast cancer. Endometrial cancers diagnosed in women treated with tamoxifen have poorer prognosis. Women who receive tamoxifen for breast cancer should be offered gynaecological surveillance during and after treatment. A long-term evaluation of the risk-benefit ratio of tamoxifen as a preventive treatment for breast cancer is clearly warranted.


Sujet(s)
Adénocarcinome/induit chimiquement , Antinéoplasiques hormonaux/effets indésirables , Tumeurs du sein/traitement médicamenteux , Tumeurs de l'endomètre/induit chimiquement , Tamoxifène/effets indésirables , Adénocarcinome/épidémiologie , Adénocarcinome/mortalité , Adulte , Sujet âgé , Antinéoplasiques hormonaux/usage thérapeutique , Tumeurs du sein/radiothérapie , Carcinome canalaire du sein/traitement médicamenteux , Carcinome canalaire du sein/radiothérapie , Études cas-témoins , Tumeurs de l'endomètre/épidémiologie , Tumeurs de l'endomètre/mortalité , Femelle , France/épidémiologie , Humains , Adulte d'âge moyen , Appréciation des risques , Analyse de survie , Tamoxifène/usage thérapeutique
17.
J Infect Dis ; 174(3): 606-9, 1996 Sep.
Article de Anglais | MEDLINE | ID: mdl-8769620

RÉSUMÉ

Using the shell vial assay and sequence analysis of a variable region of the glycoprotein B (gB) gene, cytomegalovirus (CMV) excretion rates in urine and virus transmission were studied among 93 children from six day care centers (DCCs). During a 6-month period, excretion rates differed significantly between DCCs (P < .001). The 6 gB gene sequences, obtained from 24 CMV-infected children, were classified in four previously defined groups. In five DCCs, 2 or 3 strains cocirculated, and none was dominant. Infection could have been acquired outside the DCC for 2 children and inside it for 9. Two children from the same DCC had mixed infections. No differences in hygiene, child care practices, or experience and level of qualification of the staff could explain this wide variety of excretion rates between DCCs. The distribution of gB gene patterns observed does not suggest that 1 type was dominant or more efficiently transmitted.


Sujet(s)
Infections à cytomégalovirus/transmission , Cytomegalovirus/composition chimique , Protéines de l'enveloppe virale/génétique , Séquence nucléotidique , Cytomegalovirus/isolement et purification , Variation génétique , Humains , Nourrisson , Nouveau-né , Données de séquences moléculaires , Réaction de polymérisation en chaîne , Analyse de séquence d'ADN
19.
J Am Acad Dermatol ; 34(3): 439-44, 1996 Mar.
Article de Anglais | MEDLINE | ID: mdl-8609256

RÉSUMÉ

BACKGROUND: The major factor influencing the prognosis of cutaneous malignant melanoma (MMs) is the maximum thickness of the tumor as measured by Breslow's method. However, it has been reported that thin melanomas, which should have an excellent prognosis, may have the potential to metastasize, some with an unusually rapid course. OBJECTIVE: Our purpose was to examine prognostic indicators in relation to unusually rapid aggressive behavior in patients with thin MMs (<0.76mm). METHODS: We describe nine cases of thin MM (<.76mm) that exhibited a recurrence or metastasis during a follow-up period ranging from 3 to 10 years, among computerized records of 1118 MMs treated in a multicenter epidemiologic study. The data obtained from these nine cases were compared with nonrecurring thin MM (149 cases) of the same cohort. RESULTS: The particular aggressiveness of these thin melanomas was reflected by the short disease-free interval (3 years or less) in all ine patients. The recurring thin MM more frequently involved head and neck sites, occurred in male patients, and showed Clark's level III and IV. CONCLUSION: Our review suggests that the head and neck area is particularly involved by unusually rapidly recurring thin MM. Possible explanations are the specific problems of surgical management and the greater sun exposure of this location.


Sujet(s)
Mélanome/anatomopathologie , Tumeurs cutanées/anatomopathologie , Adulte , Sujet âgé , Études de cohortes , Survie sans rechute , Femelle , Études de suivi , Tumeurs de la tête et du cou/anatomopathologie , Tumeurs de la tête et du cou/secondaire , Humains , Métastase lymphatique/anatomopathologie , Mâle , Mélanome/secondaire , Adulte d'âge moyen , Récidive tumorale locale/anatomopathologie , Stadification tumorale , Pronostic , Facteurs sexuels , Taux de survie
20.
Bull Cancer ; 81(7): 616-24, 1994 Jul.
Article de Français | MEDLINE | ID: mdl-7742605

RÉSUMÉ

The identification of factors associated with breast recurrence as first event (62 cases, 10%) following conservative surgery and radiation therapy are drawn out from a series++ of 618 mammary carcinomas of clinical size less than 40 mm, stage I and II (UICC), with a median follow up of 8 years. The most powerful predictive characteristic associated with the likelihood of breast recurrence is multiple foci of invasion (42.9% vs 8.9, P = 0.0001, relative risk [RR]: 6). After this rarely cited feature, young age, less than 40 years (20% vs 7.3%, P = 0.0001, RR: 2.8), extensive in situ carcinoma more than 25% (19.2% vs 8.7%, P = 0.003, RR: 2.5) were found also persistent in the Cox model, but not histologic size more than 25 mm (18.9% vs 9.1%, P = 0.01, RR: 2.3). The site of recurrence was studied on the 54 salvage mastectomy done. A high rate of recurrence at distance of the initial site was found: 37% whose more than half, 22%, were multicentric. No significant difference in the mean delay of appearance was noted between recurrence near or at distance of the initial cancer (mean delay 52 months vs 64 months). From the recurrence the evolution is not very favourable: excluding simultaneous metastases found at the preoperative investigation, ten cases, mammary recurrence is followed by a metastatic syndrome in 36% of cases against 17% without it (P = 0.01, RR: 1.9). Metastatic evolution is not significantly linked with the time, early or late, of the mammary recurrence (54.5% before 5 years vs 39% after) but with the association of a controlateral cancer (P = 0.03). Locally ten of the 54 mastectomy presented a thoracic recurrence, often in case of multicentric breast recurrence (P = 0.05) and not significantly when skin or areola were invaded by carcinoma.


Sujet(s)
Adénocarcinome/thérapie , Tumeurs du sein/thérapie , Récidive tumorale locale , Adénocarcinome/diagnostic , Adulte , Facteurs âges , Sujet âgé , Tumeurs du sein/diagnostic , Association thérapeutique , Femelle , Humains , Métastase lymphatique , Mastectomie partielle , Adulte d'âge moyen , Analyse multifactorielle , Stadification tumorale , Pronostic , Études rétrospectives , Facteurs de risque , Taux de survie , Facteurs temps
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE